PRESS RELEASE
For immediate release

More than 20,000 families with children aged 6 to 12 with neurodevelopmental conditions (ADD/ADHD and autism) and/or behavioural difficulties have used the application

Montreal, May 29, 2025 — MEDTEQ+ announces the Kairos testing and clinical validation project, carried out in partnership with CHU Sainte-Justine and CIUSSS du Nord-de-l’Île-de-Montréal, and with the financial support of Brain Canada. Aligned with CHU Sainte-Justine’s mission to improve the health of Quebec’s children, adolescents and mothers, the project, led by Dr. Baudouin Forgeot d’Arc – psychiatrist, researcher and head of the Department of Psychiatry at CHU Sainte-Justine – is intended to demonstrate the versatility, adaptability and clinical integration potential of Kairos, an application developed by Neuro Solutions Group. For its part, the NIM Intelliance Innovation Center at the CIUSSS du Nord-de-l’Île-de-Montréal will contribute its expertise to document the medico-economic impacts of the Kairos solution, with the aim of facilitating the adoption of this promising tool across the health and social services network.

In the context of pediatric healthcare, access to specialized interventions for children with neurodevelopmental conditions remains a priority. To better support families and respond to the diversity of needs, it is essential to implement innovative approaches that promote continuous improvement of care processes and increased accessibility to adapted services.

Used by over 20,000 families in the last few years, Kairos offers support for optimized adaptive skills, reduced behavioural symptoms, improved anger control, enhanced executive functioning and to help the child achieve emotional self-control.

“We are proud to collaborate with our member Neuro Solutions Group, a Quebec-based company that plays an essential role in providing concrete, innovative solutions through its Kairos application. Driven by the expertise of CHU Sainte-Justine and CIUSSS du Nord-de-l’Île-de-Montréal, and financially supported by the Brain Canada Foundation, this project will help improve the quality of life of many children, while providing healthcare professionals with a valuable tool for adapting their interventions and providing even better support for families”, says Annie-Kim Gilbert, PhD, President and CEO, MEDTEQ+.

“Brain Canada is proud to support evidence-based tools like Kairos that help families better care for children with neurodevelopmental conditions. By investing in research-driven tools, we help ensure that scientific advancements translate into meaningful support for those who need it most. Kairos serves as a valuable illustration of this approach”, says Dr. Viviane Poupon, President and CEO, Brain Canada.

“The collaborative support of MEDTEQ+, the Brain Canada Foundation, CHU Sainte-Justine and CIUSSS du Nord-de-l’Île-de-Montréal is crucial to the realization of this project, and Neuro Solutions Group is very grateful. Kairos is an AI-powered companion application designed to support children aged 6 to 12 facing behavioral and developmental challenges. It brings together engaging play activities for children, interactive coaching for parents and app-connected dashboards for healthcare professionals and psychosocial practitioners. Kairos offers an innovative option for access and continuity of care”, adds Annie Martineau, CEO, Neuro Solutions Group.

“Supporting the commitment of professionals, the empowerment of families and the motivation of children to develop self-regulation, promote adaptation and well-being – this is the ambition of our team at CHU Sainte-Justine in this project. This collaboration with Neuro Solutions Group, supported by MEDTEQ+ and Brain Canada, will enable us to evaluate the impact of this innovative solution in real-life care conditions, at the heart of our clinics for children living with neurodevelopmental disorders and their families”, explains Dr. Baudouin Forgeot d’Arc, principal investigator of the project and psychiatrist, researcher and head of the Department of Psychiatry, CHU Sainte-Justine.

“By participating in the evaluation of Kairos, our aim is to provide institutions with evidence of the benefits brought by the application to the entire health and social services network in terms of efficiency and value. This approach aims to enlighten decision-makers on this solution’s potential to concretely improve the follow-up of children with neurodevelopmental disorders, while documenting the gains and economic levers associated with its use. Each evaluation project we collaborate on is designed to meet the needs of the field and has the potential to make a real difference to users, and in this case, to the daily lives of families”, emphasizes Marc Pesant, Deputy Director of Innovation, CIUSSS du Nord-de-l’Île-de-Montréal.

Featuring an interface designed to collaborate with different professionals and healthcare caregivers in achieving goals of behavioural improvement, autonomy development and pharmacologically supervised care, Kairos facilitates the collection of progress information and provides relevant feedback for parents and healthcare professionals alike.

About MEDTEQ+

MEDTEQ+, a pan-Canadian consortium for industrial research and innovation in healthcare technologies, aims to accelerate the development of innovative technological solutions to improve people’s health and quality of life. MEDTEQ+ supports the validation of these technologies, their integration into the healthcare network, their commercialization, as well as their local and international outreach, by bringing together the complementary skills of industrial and institutional partners and healthcare providers. MEDTEQ+ offers support, subsidies, and investment services to innovative companies. Since December 2022, MEDTEQ+ has also been the lead partner in the envisAGE initiative, which aims to catalyze the AgeTech ecosystem and help companies grow and scale in the AgeTech market. MEDTEQ+ relies, among other things, on financial support from the Government of Quebec, the Government of Canada, the private sector, and complementary partners to foster research-industry relationships.
www.medteq.ca

About Neuro Solutions Group

Neuro Solutions Group is a leading-edge technology company dedicated to pediatric behavioral health. It develops solutions that are distinguished by their tripartite approach, aimed at developing children’s skills, providing access to support tools for parents and interactive dashboards for professionals. Neuro Solutions Group’s vision is to bridge critical gaps in access, follow-up and engagement in pediatric health care, by actively involving families while waiting for and between clinical appointments, fostering ongoing accountability and consistent day-to-day support. Neuro Solutions Group is growing rapidly in North America, notably through clinical partnerships that recognize its potential in prevention and family health support.

SOURCE :

MEDTEQ+
Information: Catherine Légaré, Senior Communication Advisor, MEDTEQ+
Contact: catherine.legare@medteq.ca

Neuro Solutions Group
Information: Annie Martineau, CEO
Contact : amartineau@neurosolutionsgroup.com